arrow_back Back to App

Faster Access to Drugs for Serious Diseases

This act aims to speed up the approval process for new drugs treating serious or life-threatening diseases. This means patients could gain quicker access to innovative therapies that might improve their health or save their lives. It also introduces new rules for monitoring the safety and effectiveness of these drugs after they are released to the market.
Key points
Accelerated Drug Approval: Drugs for serious conditions can be approved faster if early studies show promising results.
Increased Therapy Availability: Patients with serious illnesses may get quicker access to new, potentially life-saving medications.
Post-Approval Monitoring: Pharmaceutical companies will need to conduct additional studies after a drug is on the market to confirm its effectiveness and safety.
Expedited Withdrawal Option: If a drug proves ineffective or unsafe, its approval can be quickly revoked.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6996
Sponsor: Rep. McMorris Rodgers, Cathy [R-WA-5]
Process start date: 2022-03-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Accelerating Access for Patients Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6996.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-08.

What are the main provisions?

Key points include:

  • Accelerated Drug Approval: Drugs for serious conditions can be approved faster if early studies show promising results.
  • Increased Therapy Availability: Patients with serious illnesses may get quicker access to new, potentially life-saving medications.
  • Post-Approval Monitoring: Pharmaceutical companies will need to conduct additional studies after a drug is on the market to confirm its effectiveness and safety.
  • Expedited Withdrawal Option: If a drug proves ineffective or unsafe, its approval can be quickly revoked.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. McMorris Rodgers, Cathy [R-WA-5].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health